Finished Dosage Form (FDF) export of Cevidoplenib obtained from Indian Custom Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Cevidoplenib [inn], 1703788-21-9, 3n3h8bx897, Cyclopropyl-[5-[[4-[4-[[(4s)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone, Methanone, cyclopropyl(5-((4-(4-(((4s)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1h-indol-3-yl)-, Cevidoplenib [who-dd]
Molecular Formula
C25H27N7O3
Molecular Weight
473.5  g/mol
InChI Key
YCZUBLQESBVOSH-IBGZPJMESA-N
FDA UNII
3N3H8BX897

Cevidoplenib
Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B-cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage. SYK, a non-receptor cytoplasmic protein tyrosine kinase widely expressed in hematopoietic cells, plays a key role in Fc receptor and B-cell receptor signaling in inflammatory cells. It is involved in coupling activated immunoreceptors, such as Fc receptors and B-cell receptors, to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis, which are important for allergic and antibody-mediated immune diseases such as immune thrombocytopenia (ITP).
1 2D Structure

Cevidoplenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone
2.1.2 InChI
InChI=1S/C25H27N7O3/c1-15-17(10-31-12-19(33)14-35-31)11-32(29-15)23-7-8-26-25(28-23)27-18-5-6-22-20(9-18)21(13-30(22)2)24(34)16-3-4-16/h5-9,11,13,16,19,33H,3-4,10,12,14H2,1-2H3,(H,26,27,28)/t19-/m0/s1
2.1.3 InChI Key
YCZUBLQESBVOSH-IBGZPJMESA-N
2.1.4 Canonical SMILES
CC1=NN(C=C1CN2CC(CO2)O)C3=NC(=NC=C3)NC4=CC5=C(C=C4)N(C=C5C(=O)C6CC6)C
2.1.5 Isomeric SMILES
CC1=NN(C=C1CN2C[C@@H](CO2)O)C3=NC(=NC=C3)NC4=CC5=C(C=C4)N(C=C5C(=O)C6CC6)C
2.2 Other Identifiers
2.2.1 UNII
3N3H8BX897
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Cevidoplenib [inn]

2. 1703788-21-9

3. 3n3h8bx897

4. Cyclopropyl-[5-[[4-[4-[[(4s)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone

5. Methanone, Cyclopropyl(5-((4-(4-(((4s)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1h-indol-3-yl)-

6. Cevidoplenib [who-dd]

7. Unii-3n3h8bx897

8. Chembl3921923

9. Schembl16653204

10. Bdbm196772

11. Ex-a5914

12. Hy-109082

13. Cs-0039259

14. Us9212178, 1

15. (s)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1h-indol-3-yl)methanone

2.4 Create Date
2015-05-04
3 Chemical and Physical Properties
Molecular Weight 473.5 g/mol
Molecular Formula C25H27N7O3
XLogP32
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area110
Heavy Atom Count35
Formal Charge0
Complexity769
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty